DOCSLIB.ORG

Neuroleptic Malignant Syndrome Vs Serotonin Syndrome: Can They Be Distinguished Without an Underlying Etiology?

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Neuroleptic Malignant Syndrome Vs Serotonin Syndrome: Can They Be Distinguished Without an Underlying Etiology? Neuroleptic Malignant Syndrome vs Serotonin Syndrome: Can They Be Distinguished Without an Underlying Etiology? Roy R. Reeves, DO, PhD; Mark E. Ladner, MD; and Percy Smith, PA The potentially serious complications for patients with neuroleptic malignant syndrome and serotonin syndrome cannot be underplayed by mental health clinicians, patients, and their families. The authors discuss clinical similarities and diagnostic and treatment approaches to the 2 syndromes. euroleptic malignant syn- of symptoms or whether the patient ployment. He had stopped taking his drome (NMS) and sero- was taking different medications that medication (risperidone 3-mg daily) tonin syndrome (SS) are rare could affect both the serotonin and 3 months earlier, because he was Nbut potentially fatal condi- dopamine systems. experiencing adverse effects (AEs) tions associated with the treatment In clinical practice many patients and shortly thereafter hearing voices. of psychotropic medications. Neu- are treated concurrently with both The clinic psychiatrist started him on roleptic malignant syndrome is be- dopamine receptor antagonists and olanzapine 10-mg daily and sertra- lieved to be caused by a reduction in agents that increase serotonin activity. line 50-mg daily. At a follow-up visit dopaminergic activity secondary to Thus, the distinction of NMS and SS a week later, Mr. A showed an im- drug-induced dopaminergic block- may be problematic if these patients provement of his mood and reported age, whereas SS results from an ex- develop symptoms that could be at- that his hallucinations had decreased cess of central nervous system (CNS) tributed to either disorder. This article significantly. serotonin activity, usually because will discuss the clinical similarities of Several days later, Mr. A became of serotonin agonist polypharmacy NMS and SS and the treatment ap- confused and was found wander- or a drug-drug interaction involv- proaches to the 2 syndromes, as well ing around his neighborhood. He ing serotonin agonist drugs.1,2 How- as possible clues that may help to dis- was brought to the hospital by the ever, the clinical presentations of the tinguish one from the other. police. An examination at the hos- 2 syndromes are alike in many ways. pital revealed his being disheveled Neuroleptic malignant syndrome and CASE PRESENTATION and agitated. He was tremulous and SS may be difficult to distinguish if it Mr. A, a 28-year-old man with diaphoretic. His speech was loud and is not known what medications the chronic, undifferentiated schizophre- pressured. His vital signs were the patient was taking before the onset nia since his late teens, was evaluated following: heartbeat rate, 110 bpm; at the psychiatric clinic of the G.V. blood pressure (BP), 98/62; respira- Dr. Reeves is chief of psychiatry, Dr. Ladner is (Sonny) Montgomery VAMC in Jack- tion, 20 breaths/min; and tempera- a staff psychiatrist, and Mr. Smith is a physi- cian assistant, all in Mental Health Service at the son, Mississippi, where he reported ture, 102.6°F. An examination of the G.V. (Sonny) Montgomery VA Medical Center in auditory hallucinations and para- heart, lungs, and abdomen revealed Jackson, Mississippi. Dr. Reeves is a professor of noia. He also reported feeling hope- no additional evidence of pathology. psychiatry and neurology and Dr. Ladner is an as- sistant professor of psychiatry, both at the Univer- less about his future and depressed, Deep-tendon reflexes were diffusely sity of Mississippi School of Medicine in Jackson. because he could not maintain em- increased. Muscle tone in the extrem- 34 • FEDERAL PRACTITIONER • NOVEMBER 2013 ities was increased. No other physical days there, he again complained of injuries or insults, physical illness, abnormalities were detected. auditory hallucinations and depres- dehydration, rapid escalation of anti- Mr. A’s orientation was to per- sion. He was treated cautiously with psychotic dosage, use of high-potency son and year only. He could not ziprasidone and venlafaxine start- antipsychotic agents, and use of intra- recall the events of recent days. ing at low doses, which were then muscular antipsychotic agents.4 De- Laboratory findings included a titrated slowly. He was discharged hydration is a risk factor not only for white blood cell count (WBC) of 2 1/2 weeks later on ziprasidone NMS, but also for further complica- 13,800 cells/mm3 with a mild left 80-mg bid and venlafaxine 150-mg tions of NMS, explained later. shift. The chemistry survey results daily. Neuroleptic malignant syndrome were unremarkable, except for the During subsequent clinic visits, may be a serious disorder. Creati- mild elevation of the blood urea Mr. A maintained an euthymic mood. nine phosphokinase may rise to as nitrogen (BUN) (26 mg/dL)and He still experienced occasional hal- much as 60,000 IU/L. White blood creatinine (1.3 mg/dL) tests. Creat- lucinations and paranoia but was not cell counts are typically in the range inine phosphokinase (CPK) level disturbed by his symptoms. He was of 10,000 to 40,000 cells/mm3, some- was 402 IU/L. Liver function stud- able to procure and maintain em- times with a left shift.5 Possible medi- ies, serum iron level, and thyroid- ployment at a local grocery store, had cal complications are numerous and stimulating hormone results were no further episodes of agitation or can include organ failure, particularly within normal limits. The urine drug confusion, and experienced no AEs renal failure, possibly resulting from screen was negative, and the com- from his current medications. dehydration and from a large amount puted tomography scan of the head of myoglobin produced by rhabdo- and lumbar puncture findings were NEUROLEPTIC MALIGNANT myolysis. Pulmonary aspiration may unremarkable. SYNDROME occur due to dysphagia or obtunda- Determining the exact diagnosis All dopamine-blocking drugs are ca- tion. Respiratory failure may result for Mr. A’s condition was difficult. pable of precipitating NMS. Neuro- from aspiration pneumonia or de- His symptoms not only could have leptic malignant syndrome was first creased chest wall compliance. Deep been considered consistent with described in 1960 during clinical venous thrombosis and pulmonary NMS related to the recently started trials with haloperidol. Since then, embolus may occur secondary to im- olanzapine, but also with SS related NMS has been reported to occur mobility. Problems with electrolyte to the recently initiated sertraline. with all dopamine-blocking agents, imbalance may involve hypokalemia, Both medications were withheld. He including the newer atypical anti- hyponatremia, or hypernatremia. was admitted to an intensive care psychotic agents. The abrupt cessa- Other complications that have oc- unit (ICU) and closely monitored tion of dopaminergic-agonist drugs curred with NMS include myocardial and treated with supportive mea- used to treat Huntington disease and infarction, congestive heart failure, sures. In the ICU he was given intra- Parkinson disease may also produce cardiac arrhythmias, thrombocytope- 3 venous D5W 0.45% NaCl, requiring NMS-like conditions. nia, and disseminated intravascular 5 liters on the first day. He was given A large number of cases of NMS coagulation. Immobility may cause lorazepam as needed for agitation, have been reported, but many fea- pressure ulcers and related complica- receiving a total of 4 mg on the first tures of the syndrome remain contro- tions. These complications may in hospital day and 2 mg each on hos- versial. In a classic case, symptoms of some cases result in the death of the pital days 2 and 3. After 3 days his NMS include fever, autonomic insta- patient.5,6 confusion and agitation resolved, bility (BP instability and tachycardia), According to the Diagnostic and and he was able to communicate rigidity, and mental status changes. Statistical Manual of Mental Disorders, effectively. Laboratory parameters Medical students sometimes use the 4th Edition, Text Revision (DSM-IV- returned to normal ranges, includ- mnemonic FARM to recall this con- TR), the diagnosis of NMS should ing WBC, 8,700 cells/mm3; BUN, stellation of symptoms. Neuroleptic be assigned only to patients who de- 19 mg/dL; creatinine, 0.9 mg/dL; and malignant syndrome is frequently velop severe muscle rigidity and el- CPK, 190 IU/L. misdiagnosed and can be fatal in evated temperature while receiving Intravenous fluids were discon- 5% to 20% of patients if untreated.4 a neuroleptic drug and who display tinued, and Mr. A was transferred Risk factors for NMS include young 2 or more of the following signs and to a psychiatric unit. Within a few age, male gender, preexisting brain symptoms: diaphoresis, dysphagia, NOVEMBER 2013 • FEDERAL PRACTITIONER • 35 Neuroleptic Malignant Syndrome vs Serotonin Syndrome Table. Clues that may help distinguish neuroleptic malignant clinical presentation. The mortality rate of SS is unknown; the disorder syndrome and serotonin syndrome when no precipitating may resolve quickly with removal of 3,5,16,18 agent can be identified the offending agent(s) or may be po- Clinical course tentially fatal.6 Specific risk factors for SS have not been identified beyond Rapid onset and progression: More likely SS serotonin polypharmacy, such as the Rapid resolution: More likely SS potentially fatal combination of a se- Clinical symptoms lective serotonin reuptake inhibitor (SSRI) and a monoamine oxidase in- Gastrointestinal symptoms: More likely SS hibitor (MAOI).3 Shivering: More likely SS A review by Sternbach with sug- gested diagnostic criteria was pub- Clinical signs lished in 1991.11 Sternbach proposed Severe rigidity: More likely NMS criteria that included the occurrence Myoclonus: More likely SS concomitant with the addition of a serotonergic agent to an established Hyperreflexia: More likely SS medication regimen of at least 3 of Laboratory findings the following features: mental status changes (confusion, hypomania), ag- Severely elevated CPK: More likely NMS itation, myoclonus, hyperreflexia, di- Severely elevated WBC: More likely NMS aphoresis, shivering, tremor, diarrhea, Low serum iron levels: More likely NMS incoordination, or fever.
Load more

Recommended publications
  • Canadian Stroke Best Practice Recommendations
    CANADIAN STROKE BEST PRACTICE RECOMMENDATIONS MOOD, COGNITION AND FATIGUE FOLLOWING STROKE Table 1C: Summary Table for Selected Pharmacotherapy for Post-Stroke Depression Update 2019 Lanctôt KL, Swartz RH (Writing Group Chairs) on Behalf of the Canadian Stroke Best Practice Recommendations Mood, Cognition and Fatigue following Stroke Writing Group and the Canadian Stroke Best Practice and Quality Advisory Committee, in collaboration with the Canadian Stroke Consortium © 2019 Heart & Stroke Heart and Stroke Foundation Mood, Cognition and Fatigue following Stroke Canadian Stroke Best Practice Recommendations Table 1C Table 1C: Summary Table for Selected Pharmacotherapy for Post-Stroke Depression This table provides a summary of the pharmacotherapeutic properties, side effects, drug interactions and other important information on selected classes of medications available for use in Canada and more commonly recommended for post-stroke depression. This table should be used as a reference guide by health care professionals when selecting an appropriate agent for individual patients. Patient compliance, patient preference and/or past experience, side effects, and drug interactions should all be taken into consideration during decision-making, in addition to other information provided in this table and available elsewhere regarding these medications. Selective Serotonin Reuptake Inhibitors (SSRI) Serotonin–norepinephrine reuptake Other inhibitors (SNRI) Medication *citalopram – Celexa *duloxetine – Cymbalta methylphenidate – Ritalin (amphetamine)
    [Show full text]
  • The Pharma-Fever That Almost Got Away
    EMERGENCY MEDICINE RESIDENCY CPC The pharma-fever that almost got away XIAO CHI ZHANG, MD, MS; MATTHEW SIKET, MD; WILLIAM BINDER, MD 29 31 EN From the Case Records of the Alpert Medical School of DR. SARAH GAINES: A fever greater than 41.0°C is quite Brown University Residency in Emergency Medicine elevated and unusual. Is this dangerous? What was your differential? DR. XIAO CHI ZHANG: A 68-year-old man was brought into DR. MATTHEW SIKET: Humans generally tolerate tempera- the Emergency Department by his family with chills and tures below 41° C (105.8° F). In contrast to hyperthermia, in altered mental status. Two days prior to his ED presenta- which an imbalance between heat generation versus dissipa- tion, the patient had an episode in which he “spaced-out” tion occurs without up-regulation of the hypothalamic set and was unable to comprehend or acknowledge his wife. She point, fever as a host defense against infection rarely reaches reported that he did not have any signs of seizure activity dangerous levels in neurologically competent individuals. and did not have any focal weakness. The episode lasted Very high temperatures can be related to urosepsis, intraab- approximately 30 minutes and he returned to his baseline. dominal sepsis, C. difficile colitis, meningitis, and central Today he had another episode, but this time associated with venous catheter infections. Hyperpyrexia, defined as tem- chills and rigors. His past medical history was significant perature > 41.5°C (106.7°F) is an uncommon result of infec- for chronic back pain due to bony metastasis from Stage IV tion and usually implies central fever, neurologic malignant non-small cell lung adenocarcinoma, requiring palliative syndrome, malignant hyperthermia, adrenal insufficiency, gamma knife radiation, as well as a daily oral chemotherapy or a drug related cause.1 Our patient was hyperpyrexic, sug- agent, erlotinib, an oral tyrosine kinase inhibitor.
    [Show full text]
  • PRESCRIBED DRUGS and NEUROLOGICAL COMPLICATIONS K a Grosset, D G Grosset Iii2
    J Neurol Neurosurg Psychiatry: first published as 10.1136/jnnp.2004.045757 on 16 August 2004. Downloaded from PRESCRIBED DRUGS AND NEUROLOGICAL COMPLICATIONS K A Grosset, D G Grosset iii2 J Neurol Neurosurg Psychiatry 2004;75(Suppl III):iii2–iii8. doi: 10.1136/jnnp.2004.045757 treatment history is a fundamental part of the healthcare consultation. Current drugs (prescribed, over the counter, herbal remedies, drugs of misuse) and how they are taken A(frequency, timing, missed and extra doses), drugs tried previously and reason for discontinuation, treatment response, adverse effects, allergies, and intolerances should be taken into account. Recent immunisations may also be of importance. This article examines the particular relevance of medication in patients presenting with neurological symptoms. Drugs and their interactions may contribute in part or fully to the neurological syndrome, and treatment response may assist diagnostically or in future management plans. Knowledge of medicine taking behaviour may clarify clinical presentations such as analgesic overuse causing chronic daily headache, or severe dyskinesia resulting from obsessive use of dopamine replacement treatment. In most cases, iatrogenic symptoms are best managed by withdrawal of the offending drug. Indirect mechanisms whereby drugs could cause neurological problems are beyond the scope of the current article—for example, drugs which raise blood pressure or which worsen glycaemic control and consequently increase the risk of cerebrovascular disease, or immunosupressants
    [Show full text]
  • Catatonia, NMS, and Serotonin Syndrome
    Catatonia, NMS, and Serotonin Syndrome Christopher M. Celano, MD, FACLP Associate Director, Cardiac Psychiatry Research Program, Massachusetts General Hospital Assistant Professor of Psychiatry, Harvard Medical School October 22, 2020 www.mghcme.org Disclosure: Christopher Celano, MD Sunovion Company Pharmaceuticals Employment Management Independent Contractor Consulting Speaking & Teaching I Board, Panel or Committee Membership D – Relationship is considered directly relevant to the presentation I – Relationship is NOT considered directly relevant to the presentation www.mghcme.org Catatonia: How common is it? • 7.8-9.0% prevalence rate – Highest rates in non-psychiatric (i.e., medical) settings and in patients undergoing ECT. • 1.6-5.5% of all patients seen on psychiatry consultation service – Prevalence higher for older patients • Up to 46% of cases may have etiology that is not primarily psychiatric Grover 2015, Carroll 1994, Jaimes-Albornoz 2013, Fricchione 2008 www.mghcme.org When are you called? • Staff reports the patient is “Playing POSSUM” • Perseveration (speech or behavior) • Oppositionality to all requests • Speech that trails off or is whispereD • Slowed response to questions or commands • Undernourished (reports of decreased PO intake) • Motionless but awake www.mghcme.org Diagnosing Catatonia: DSM-5 DSM-5 requires 3 or more of the following: • Catalepsy • Posturing • Waxy flexibility • Mannerisms • Stupor • Stereotypies • Agitation • Grimacing • Mutism • Echolalia • Negativism • Echopraxia American Psychiatric Association 2013 www.mghcme.org Bush-Francis Rating Scale • Excitement • VerBigeration • Immobility/stupor • Rigidity • ComBativeness • Negativism • Autonomic Abnormality • Waxy flexiBility • Impulsivity • Withdrawal • Mutism • Automatic OBedience • Staring • Mitgehen • Posturing/catalepsy • Gegenhalten • Grimacing • AmBitendency • Echopraxia/echolalia • Grasp Reflex • Stereotypy • Perseveration • Mannerisms Bush 1996 www.mghcme.org Challenges with Diagnosis • Clarifying specific symptoms can be difficult – Rigidity vs.
    [Show full text]
  • Triptan Therapy for Acute Migraine
    Triptan Therapy for Acute Migraine Headache John Farr Rothrock, MD University of Alabama at Birmingham, Birmingham, AL Deborah I. Friedman, MD, MPH University of Texas Southwestern, Dallas, TX The “triptans” are 5HT-1B/1D receptor agonists that were developed to treat acute migraine and acute cluster headache. Sumatriptan, the original triptan preparation, has been in general use since 1993, so there has been considerable experience with triptans over time. There are currently seven oral triptans on the market in the United States: sumatriptan (Imitrex™), naratriptan (Amerge™), zolmitriptan (Zomig™), rizatriptan (Maxalt™), almotriptan (Axert™), frovatriptan (Frova™), and eletriptan (Relpax™); brand names may differ by country. There is also a combination preparation of oral sumatriptan/naproxen (Treximet™). Two triptans (sumatriptan, zolmitriptan) are marketed as nasal sprays, and sumatriptan is available for subcutaneous injection, including a needle-free subcutaneous delivery system (Sumavel™). Sumatriptan suppositories are marketed in Europe but not in North America. Zolmitriptan and rizatriptan are sold in an oral disintegrating tablet or “melt” formulation as well as in tablet form; while the “melt” formulations may be more convenient (no liquid is required to propel them into the stomach), they are absorbed similarly to regular tablets and there is no evidence to suggest that they work faster than the tablet formulations. Some patients with migraine-associated nausea prefer the disintegrating tablets while others cannot tolerate their taste. Although all of the triptans initially were investigated for the treatment of migraine headache of moderate to severe intensity and were superior to placebo in those pivotal trials, they appear to be more consistently effective when used to treat migraine earlier in the attack, when the headache is still mild to moderate.
    [Show full text]
  • JAMA Neurology Pages 525-636
    In This Issue May 2018 Volume 75, Number 5 JAMA Neurology Pages 525-636 Research Opinion Amyloid and Tau Accumulation in Young Adults With ADAD 548 Viewpoint 531 Preventing Sudden Unexpected Although the medial temporal lobe is typically the first area of neurofibrillary tangle depo- Death in Epilepsy sition in aging populations, it is not clear if this is the case for younger individuals who are O Devinsky and Coauthors predisposed to autosomal dominant Alzheimer disease (ADAD). In a cross-sectional study, Quiroz and coauthors used positron emission tomography imaging to measure amyloid and Clinical Review & Education tau deposition in 24 participants (mean [SD] age, 38.0 [7.4] years) from a large Colombian Review kindred with ADAD. The authors report that amyloid accumulates in the cortex of unim- paired presenilin 1 E280A mutation carriers 10 to 15 years before symptom onset, whereas tau deposits emerge in the medial temporal lobe approximately 6 years before and then spread into the cortex as carriers move closer to clinical onset. These findings suggest that amyloid prompts the spread of tau pathology beyond the medial temporal lobe and that the presence of tau is closely associated with memory decline. Editorial perspective is pro- vided by McDade and Bateman. Editorial 536 Risk of Serotonin Syndrome With Triptans and Antidepressants 566 In 2006, the US Food and Drug Administration issued a warning regarding the potential risk of serotonin syndrome with coprescription of triptan antimigraine drugs and selective sero- 620 Review of the Neurological toninreuptakeinhibitororselectivenorepinephrinereuptakeinhibitorantidepressantsbased Implications of von Hippel–Lindau Disease D Dornbos III and Coauthors on a small number of case reports.
    [Show full text]
  • Catatonia, Serotonin Syndrome and Parkinsonism
    MJP Online Early 01-01-17 CASE REPORT A Diagnostic Dilemma: Catatonia, Serotonin Syndrome and Parkinsonism Mohd Miharbei MF1,2, Ahmad Zafri AB1, Suhaila MZ1 1Jabatan Psikiatri dan Kesihatan Mental, Hospital Tengku Ampuan Afzan, 25100 Kuantan, Pahang, Malaysia 2Department of Psychological Medicine, Faculty of Medicine, University of Malaya, 50603 Kuala Lumpur, Malaysia Abstract Catatonia may concomitantly occur with other psychiatric diagnoses such as Major Depressive Disorder, however problem in diagnosis may arise due to the overlapping features with other problems such as serotonin syndromes, neuroleptic malignant syndromes and Parkinsonism. Despite the diagnostic dilemma and lack of diagnostic tools, the clinical correlation between the carbon monoxide poisoning and the late-onset development of the Parkinsonian features is the highlight of this report. Keywords: Catatonia, Parkinsonism, Carbon Monoxide Poisoning Introduction symptoms such as stuporous nature of the patient, rigidity, tremor and bradykinesia. Catatonic syndromes are a diagnostic conundrum and always offer a therapeutic Despite the similarity, the option and challenge as well. Catatonia is an associated response towards treatment are quite feature in major psychiatric diagnoses, as different. While electroconvulsive therapy is well as a prominent overlapping features in a known treatment option in catatonic state, neuroleptic malignant syndrome, akinetic it may not be the case for the state of parkinsonism and representing motor serotonergic syndrome and Parkinsonism. features of serotonergic syndromes [1,3]. The list of the possible cause of similar Case report presentations are vast. Among others, carbon monoxide poisoning is known to Mr LHC, a 58 years old Chinese male, with cause delayed onset Parkinsonism [2]. background history of methamphetamine abuse, presented to the hospital following Among the said differentials, there are few unconsciousness episode at home.
    [Show full text]
  • Serotonin Syndrome in Stroke Patients
    J Rehabil Med 2015; 47: 282–285 CASE REPORT Serotonin SYNDROME IN STROKE patients Sung Ho Jang, MD1*, Yong Min Kwon, MD1* and Min Cheol Chang, MD2 From the 1Department of Physical Medicine and Rehabilitation, College of Medicine, Yeungnam University and 2Department of Physical Medicine and Rehabilitation, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea. *These authors contributed equally to this study. Objective: Serotonin syndrome is a potentially life-threaten- Dopaminergic agents are known to be effective in improve- ing condition that can be caused by administration of agents ment of cognitive, language, motor, and executive function that increase serotonergic activity in the brain. We report in stroke patients (3). Therefore, dopaminergic drugs are here on 2 stroke patients who presented with serotonin syn- often prescribed for stroke patients during rehabilitation; drome following administration of dopaminergic agents. however, administration of dopaminergic drugs is associated Case report: Two stroke patients were administered ropin- with the risk of inducing SS (1, 4, 5). Although SS has been irole (patient 1) and carbidopa/levodopa (patient 2) during reported in other brain pathologies, including depressive rehabilitation. Both patients exhibited the clinical features of disorder and Parkinson’s disease, little is known about SS in serotonin syndrome, coinciding with an increase in dosage of stroke patients (5). each drug. Based on the clinical features included in revised We report here on 2 stroke patients who presented with SS Radomski’s criteria, they presented with 3 major symptoms after administration of dopaminergic agents. with 3 and 2 minor symptoms, respectively. The drugs that were thought to trigger serotonin syndrome were discontin- ued and the patients underwent conservative treatment.
    [Show full text]
  • Diagnosis of Serotonin Syndrome in the Intensive Care Population: a Case Report
    Netherlands Journal of Critical Care Accepted December 2013 CASE REPORT Diagnosis of serotonin syndrome in the intensive care population: a case report X. Zuidema1, I. Wilting2, M. Kromkamp3, J. Kesecioglu1 1Department of Intensive Care Medicine, Division of Anesthesiology, Intensive Care and Emergency Medicine Department of Intensive Care Medicine, University Medical Center Utrecht, the Netherlands 2Department of Clinical Pharmacy, Division Laboratory and Pharmacy, University Medical Center Utrecht, the Netherlands 3Department of Psychiatry, University Medical Center Utrecht, the Netherlands Correspondence X. Zuidema – e-mail: [email protected] Keywords – Serotonin syndrome, ICU, diagnosis Abstract by rapid treatment, however, is crucial, since a significant ICU admission due to serotonin syndrome (SS) is well proportion of SS cases (17%) lead to a worse outcome, with a described in the literature. However, development of SS during mortality rate of up to 0.2%.3 SS is mostly seen as a result of ICU admission has not been reported to date. We present a inadvertent interactions between serotonin-active drugs and/ patient in whom SS was suspected during ICU admission. or intentional self-poisoning.4,5 We describe a patient who was SS may be induced by either increased serotonergic activity suspected of SS during ICU admission, whilst continuing a or by lowering the cerebral serotonin sensitivity threshold. medication regime that included citalopram and amitriptyline. SS is not easily recognized, especially in ICU populations because it can easily be confused with clinical deterioration Case report or other drug-related toxidromes. SS is a potentially fatal A fifty-five year old somnolent male was admitted to the clinical syndrome, which requires rapid diagnosis and timely Department of Internal Medicine of a large academic teaching treatment.
    [Show full text]
  • Movement Disorders Emergencies Part 1 Hypokinetic Disorders
    NEUROLOGICAL REVIEW SECTION EDITOR: DAVID E. PLEASURE, MD Movement Disorders Emergencies Part 1 Hypokinetic Disorders Bradley J. Robottom, MD; William J. Weiner, MD; Stewart A. Factor, DO ovement disorders usually do not require emergent intervention; nevertheless, there are acute/subacute clinical settings in which the neurologist is consulted. It is in these circumstances that the neurologist must be prepared to accurately diagnose and properly treat the patient. We have reviewed the literature regarding move- Mment disorder emergencies and divided them into hypokinetic (part 1) and hyperkinetic (part 2) presentations. In part 1, drug-induced syndromes including neuroleptic malignant syndrome, par- kinsonism hyperpyrexia syndrome, and serotonin syndrome will be discussed. Emergency com- plications related to the management of Parkinson disease, including falling, motor fluctuations, and psychiatric issues, will also be reviewed. Arch Neurol. 2011;68(5):567-572 Movement disorders often have an insidi- DRUG-INDUCED MOVEMENT ous onset and slow progression and are not DISORDER EMERGENCIES often associated with emergency situa- tions. However, neurologists may be called Neuroleptic Malignant Syndrome on to diagnose and treat evolving move- ment disorders or acute complications of Neuroleptic malignant syndrome, first de- existing diseases in the emergency depart- scribed in 1960,2 is an iatrogenic disorder re- ment or intensive care unit. Such situa- sulting from exposure to drugs that block tions meet the working definition of an dopamine
    [Show full text]
  • Serotonin Syndrome in Asymptomatic Huntington's Disease
    Serotonin syndrome I Case notes Serotonin syndrome in asymptomatic Huntington’s disease Verity Haffenden BSc, MBBS, Anish Patel MBChB, MRCPsych, MedEd(Cert) Serotonin syndrome is a rare Figure 1. Hunter’s Criteria (adapted from Boyer and Shannon, 2005)6 and serious condition most often resulting from iatrogenic insult; the prescriber’s pen is Has a serotonergic agent been administered in the past five weeks? sometimes the most poisonous. Here, Dr Haffenden and Dr No Yes Patel discuss a complex case of serotonin syndrome in a patient with genetically proven, but not Not serotonin Are any of the following symptoms yet symptomatic, Huntington’s syndrome present? disease and chronic renal Tremor and hyperreflexia impairment. A screening Spontaneous clonus process is proposed to recognise the multitude of No Muscle rigidity, temperature >38°C, and Yes precipitating factors, which either ocular clonus or inducible clonus aligned in this case, and could Ocular clonus and either agitation or either alter our prescribing or diaphoresis expedite recognition. Inducible clonus and either agitation or diaphoresis untington’s disease (HD), a Hprogressive neurodegenerative Not serotonin Serotonin disease, is clinically diagnosed with syndrome syndrome a triad of signs/symptoms: chorea; psychiatric illness, and dementia. Research has shown neurotransmit- surgery was performed using a Past medical history of note ter deficits in mice models of Hun- cadaveric specimen but his postoper- included a genetic, but not yet tington’s1 both before and after ative period was complicated by anti- symptomatic, diagnosis of HD and symptomatic disease presence2 – body-mediated rejection and past psychiatric history included namely a reduction in serotonin.
    [Show full text]
  • Serotonin Syndrome: a Concise Review of a Toxic State Dwayne R
    RHODE ISLAND M EDICAL J OURNAL THE CORNER brown’s new DRUGSTORE ARONSON FUND PAGES 10–12 PAGE 75 SPECIAL SECTION IDENTIFYING and MANAGING PSYCHIATRIC EMERGENCIES COLIN J. HARRINGTON, MD; ROBERT BOLAND, MD; GUEST EDITORS JUNE 2014 VOLUME 97• NUMBER 6 ISSN 2327-2228 Some things have changed in 25 years. Some things have not. Since 1988, physicians have trusted us to understand their professional liability, property, and personal insurance needs. Working with multiple insurers allows us to offer you choice and the convenience of one-stop shopping. Call us. 800-559-6711 rims I B C RIMS-INSURANCE BROKERAGE CORPORATION Medical/Professional Liability Property/Casualty Life/Health/Disability RHODE ISLAND M EDICAL J OURNAL 16 Identifying and Managing Psychiatric Emergencies COLIN J. HARRINGTON, MD; ROBERT BOLAND, MD GUEST EDITORS Colin J. Harrington, MD Robert Boland, MD 18 Delirium: Presentation, Epidemiology, and Diagnostic Evaluation (Part 1) COLIN J. HARRINGTON, MD; KALYA VARDI, MD 24 Delirium: Treatment and Prevention (Part 2) KALYA VARDI, MD; COLIN J. HARRINGTON, MD Kalya Vardi, MD 29 The ‘Problem Patient’: Modest Advice for Frustrated Clinicians ROBERT BOLAND, MD 33 Serotonin Syndrome: A Concise Review of a Toxic State DWAYNE R. HEITMILLER, MD Jeffrey Burock, MD 36 Practical Management of Alzheimer’s Dementia JEFFREY BUROCK, MD; LILLY NAQVI, BS 41 Emerging Drugs of Abuse: Clinical and Legal Considerations ELIE G. AOUN, MD; PAUL P. CHRISTOPHER, MD; Elie G. Aoun, MD JAMES W. INGRAHAM, MD RHODE ISLAND M EDICAL J OURNAL 7 COMMENTARY Retirement: For Better or Worse? JOSEPH H. FRIEDMAN, MD The Moral Heritage of the Corner Drugstore STANLEY M.
    [Show full text]